Screener
Palvella Therapeutics PVLA Noncash Interest Expense Income Royalty Agreement
Noncash Interest Expense Income Royalty Agreement at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:NoncashInterestExpenseIncomeRoyaltyAgreement.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
FAQ
- What is Palvella Therapeutics's noncash interest expense income royalty agreement?
- Palvella Therapeutics (PVLA) reported noncash interest expense income royalty agreement of $2.04M in Q1 2026.
- How has Palvella Therapeutics's noncash interest expense income royalty agreement changed year-over-year?
- Palvella Therapeutics's noncash interest expense income royalty agreement increased by 67.8% year-over-year, from $1.22M to $2.04M.
- What does noncash interest expense income royalty agreement mean?
- Represents the non-cash portion of interest expense or income associated with royalty-based financing arrangements. This adjustment accounts for the amortization or accretion of royalty obligations that do not involve immediate cash outflows or inflows. It is essential for reconciling net income to cash flow from operations in companies utilizing royalty monetization strategies.
Ask your AI about Palvella Therapeutics's noncash interest expense income royalty agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude